Stratification of Patient With Carotid Disease

Aim of the trial is to validate TAXINOMISIS system for risk stratification of carotid artery stenotic disease. Primary endpoints are stroke, transitory ischemic attack or retinal symptom while secondary endpoints are MRI silent brain lesions and carotid plaque progression.

Patient with moderate to severe extra-cranial, both asymptomatic and symptomatic, carotid artery stenosis will be enrolled in the prospective observational multi-center trial in five European (Athens, Barcelona, Belgrade, Genoa, Munich and Utrecht) vascular centers. Inclusion will last from 31.3.2018 - 01.06.2019. Patients with short life expectancy, high potential of stroke from other cause or patients with complex and tandem carotid lesions will be excluded from the trial.

Included patients will be examined clinically, basic laboratory exam will be performed and part of blood specimen will be stored and assessed later. Carotid plaque will be analysed by means of duplex and MRI image while brain lesions will be detected on brain MRI.

Treatment strategy will be dependent on guidelines of good clinical practice and let independently to institutional multidisciplinary panelist board. In patients treated with carotid endarterectomy (CEA) carotid plaque will be stored and assessed for future analysis. In respect to allocated therapy patients will follow different follow up protocols.

Intervention group: Patients undergoing intervention CEA or carotid artery stenting (CAS), will be followed by clinical examination and carotid duplex on 12, 24 and 36 month. If there is coexisting contralateral carotid stenosis greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.

Optimal medical therapy group: Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contra-lateral stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.

Trial plans to recruit 270 patients distributed in participating centers based on individual capabilities of each center. The diagnostic performance of the new risk model, and its accuracy to discriminate high versus low risk cases for cerebrovascular complications from carotid artery disease will be evaluated using Receiver Operating Characteristic (ROC) curve analysis. The accuracy (discriminated ability) of the model will be assessed by measuring the Area under the ROC curve (AUC). An AUC 0.80 and 90% CI, for the sensitivity of prediction model of 80% with marginal error of 10%, will be targeted.

Trial will terminate after finalizing 36 months of follow up for included patients at June 2022.

Inclusion criteria

• Extracranial carotid stenosis greater than 50% stenosis (NASCET) in the carotid bifurcation or internal carotid artery assessed by means of ultrasound;
• Ability of the patient for follow-up examinations;
• Personally signed informed consent

Exclusion criteria

• Previous haemorrhagic stroke,
• Non-atherosclerotic carotid stenosis (e.g. dissection, floating thrombus, fibromuscular dysplasia, postirradiation lesion)
• Presence of stenotic lesions in the proximal common carotid artery,
• Recurrent carotid stenosis after CEA or CAS,
• Carotid aneurysm
• Bilateral carotid occlusion,
• Severe aortic arch calcifications and shaggy aorta
• Intracranial angioma or aneurysms,
• Severe pre-existing disability (modified Rankin scale ≥ 3);
• Contraindications for heparin, ASA and clopidogrel therapy
• Contraindication for MRI examination (metal implants, claustrophobia);
• Increased risk of thrombotic or embolic events (congenital or acquired thrombotic conditions, active untreated cancer, atrial fibrillation, severe cardiomyopathy with ejection fraction lower than 30%);
• Planned major surgery and/or life expectancy less than 3 years